Supplementary Figure 2 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

Autor: Alessandro D. Santin, Wim H.A. Dokter, C. Marco Timmers, Miranda M.C. van der Lee, Patrick H. Beusker, Peter Goedings, Peter E. Schwartz, Babak Litkouhi, Masoud Azodi, Dan-Arin Silasi, Elena Ratner, Salvatore Lopez, Serena Wong, Pei Hui, Natalia Buza, Emiliano Cocco, Christopher De Haydu, Federica Predolini, Francesca Ferrari, Elena Bonazzoli, Carlton L. Schwab, Stefania Bellone, Gulden Menderes, Jonathan Black
Rok vydání: 2023
Popis: Exposure of all nine cell lines to scalar concentrations of ADC for a total of 6 days. IC50 dose response curves of SYD985, T-DM1 and ADC isotype control in all 9 primary USC cell lines with differential HER2 expression tested in vitro (i.e., three with HER2 3+ expression, two with HER2 2+ expression and four with HER2 1+ expression) at 6 days (ie, 144 hrs).
Databáze: OpenAIRE